Authors
Latest:
Matthew Frank, MD, PhD, on Tackling Antigen Loss and Absence in Hematological MalignanciesThe assistant professor of medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University discussed potential methods for optimizing CAR-T efficacy that could be explored in the future.
Latest:
Trials Examining Cilta-Cel in Relapsed/Refractory Multiple Myeloma: Mansi R. Shah, MDThe hematologist/oncologist from Rutgers Cancer Institute of New Jersey discussed ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel.
Latest:
CAR T Therapy in Non-Hodgkin Lymphoma: Kelly Garvin, BSN, RNThe lymphoma specialist from Moffitt Cancer Center discussed the advantages of CAR T-cell therapy in non-Hodgkin lymphoma.
Latest:
James Lim, PhD, on Addressing Lingering Needs in Research Process Development and Clinical ManufacturingThe cofounder and chief scientific officer of Xcell Biosciences discussed the company’s efforts to introduce new technologies for improving cell therapy development and manufacturing.
Latest:
Arshad Khanani, MD, on Comparing Wet AMD Gene Therapy 4D-150 to Aflibercept in a Randomized Clinical TrialThe assistant professor in the department of pediatrics at the University of Florida College of Medicine discussed also discussed the latest results announced from the phase 2 portion of the PRISM study.
Latest:
CAR T and Other Options for Relapsed/Refractory Follicular Lymphoma: Javier L. Munoz, MD, MS, FACPThe director of Mayo Clinic's Lymphoma Program discussed R/R FL and current treatment options.
Latest:
Paul Stewart, PhD, on the Potential of Genetic Medicine Approaches in Squamous Cell Lung CancerThe assistant member at the Department of Biostatistics and Bioinformatics at Moffitt Cancer Center shared the potential implications of the findings he is presenting at the 2023 AACR annual meeting on proteomics and metabolomics.
Latest:
ASCT Utilization Rates in Mantle Cell Lymphoma: Yazeed Sawalha, MDThe hematologist at Ohio State University Comprehensive Cancer Center–The James discussed utilization rates of autologous stem cell transplant in patients with mantle cell lymphoma.
Latest:
Juan Francisco Cabello, MD, on How Gene Therapy Fits Into the Global Initiative for Newborn ScreeningThe head of the Pediatric Neurology Fellowship Program at the University of Valparaiso in Chile discussed how a lack of cost-effectiveness may hold back the potential of newborn screening in gene therapy.
Latest:
Gerhard Ehninger, MD, on Managing Toxicities With Switchable CARs in AMLThe professor at University Hospital Dresden discussed the positive safety profile of Unicar-T-CD123.
Latest:
Matt Angel, PhD, on Addressing Unmet Needs in Acute Myeloid Leukemia and Solid TumorsThe chief executive officer and president of Eterna Therapeutics discussed the company’s new collaboration with the University of Texas MD Anderson Cancer Center.
Latest:
Combining RNA and CAR T-Cell Therapy for Myasthenia GravisMichael Singer, MD, PhD, cofounder and chief scientific officer of Cartesian Therapeutics, discussed the company’s lead candidate, Descartes-08.
Latest:
Evaluating Engineered Tregs for Potential in Treating Multiple SclerosisTravis Drow, BS, a research scientist at Seattle Children's Research Institute, discussed mouse model research he presented at ASGCT’s 2024 Meeting.
Latest:
Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCLClosing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.
Latest:
Adham Bear, MD, On Immunotherapy Targeting Mutant KRASThe instructor of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania discussed his thoughts on the potential of targeting mutant KRAS with immunotherapy.
Latest:
Harikrishna Nakshastri, PhD, on Characterizing Early Oncogenesis in Breast CancerThe professor of breast cancer research at Indiana University discussed new research with the TONSL gene from Indiana University.
Latest:
Erika Fullwood Augustine, MD, MS, on Optimizing End Points for Rare Disease Clinical TrialsThe associate chief science officer of the Kennedy Krieger Institute discussed an aspect of clinical trial design highly relevant to gene therapy development for rare diseases.
Latest:
Susan Foy, PhD, on Evaluating Personalized, Neoantigen-Specific T Cell Therapy in Solid TumorsThe CRIPSR-edited neoantigen-specific T cell therapy demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC 2022.
Latest:
Susie Long, PharmD, on ASTCT’s 2023 Fundamentals of HCT Training CourseThe pediatric clinical pharmacist in stem cell transplant and cellular therapy at the University of Minnesota Masonic Children’s Hospital and M Health Fairview offered an in-depth preview of the upcoming virtual meeting.
Latest:
Robert M Califf, MD, MACC, on 2023’s Landmark FDA Approvals of Cell and Gene TherapiesThe commissioner of food and drugs at the FDA discussed the year's approvals and what may be coming on the horizon in the realm of advanced therapeutics.
Latest:
Brian Culley, MS, on Sharing Knowledge From the Development of Spinal Cord Injury Cell TherapyThe chief executive officer of Lineage Cell Therapeutics discussed findings related to its cell therapy OPC1 that the company presented at the first Annual SCI Investor Symposium.
Latest:
Jakub Svoboda, MD, On Improving CR Rates With Next-generation CAR T TherapiesThe associate professor of medicine from University of Pennsylvania discussed advantages of huCART19-IL18 in NHL and CLL.
Latest:
Looking Forward in Relapsed/Refractory Multiple Myeloma TreatmentsJames Hoffman, MD, leads a discussion about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.
Latest:
Thomas McCauley, PhD, on Proof-of Concept With In Vivo Epigenomic EditingThe chief scientific officer at Omega Therapeutics discussed how the MYCHELANGEO-1 trial may validate the company’s OEC platform.
Latest:
Developing Gene Therapies for Indications With Unmet NeedsThe chief executive and scientific officers of Lysogene discussed Lysogene’s patient-focused therapy development.
Latest:
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease BiologyThe associate professor of clinical pediatrics at Cincinnati Children's discussed further investigations into novel therapies and new research.
Latest:
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024The scientist from Krembil Research Institute shared takeaways from the session she chaired.
Latest:
Overcoming Barriers to TIL Use in Patients With Solid TumorsClosing out their discussion on TIL therapy, Drs Sarnaik and Komanduri identify existing barriers to TIL use in clinical practice and how the field might optimize patient access to these regimens.
Latest:
Michael Leek, PhD, on Manufacturing Challenges in Cell TherapyThe co-founder and executive chairman of TC BioPharm discussed his thoughts on the regulatory, logistical, and quality hurdles of manufacturing cell therapies.
Latest:
Mathula Thangarajh, MD, PhD, on the Potential of Gene Therapy to Address Cognitive Symptoms in Muscular DystrophyThe child neurologist and neuromuscular physician at Virginia Commonwealth University also discussed the session she chaired at the 2023 MDA Clinical and Scientific Conference.
